RecruitingNot ApplicableNCT07295171

HELP Study - Towards High Throughput and Efficient Long-axial PET With Oral [18F]FDG


Sponsor

British Columbia Cancer Agency

Enrollment

27 participants

Start Date

Feb 18, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

Typically, PET scans involve an IV injection of 18F-FDG that helps identify cancer. Patients are scanned 60 minutes after injecting 18F-FDG. This study aims to assess the feasibility of a different method of administration - oral ingestion (rather than IV) of 18F-FDG through delayed imaging to identify the optimal time for scanning after consuming the drug. The study will aim to recruit 15-24 individuals who will receive two PET scans - one using delayed oral 18F-FDG imaging and a second regular 18F-FDG. The analysis will focus on establishing a suitable protocol for this administration route while considering patient preference and image quality.


Eligibility

Min Age: 19 Years

Inclusion Criteria4

  • Age ≥19 years
  • Participants who have received a standard of care \[18F\]FDG PET/CT and are willing to undergo a study specific oral \[18F\]FDG PET/CT within 2 weeks.
  • Age ≥19 years
  • Participants who have received a standard of care \[18F\]FDG PET/CT and are willing to undergo a study specific oral \[18F\]FDG PET/CT within 2 weeks.

Exclusion Criteria13

  • Pregnant or breast-feeding
  • Medically unstable (e.g., acute illness, unstable vital signs)
  • Urinary incontinence/catheter.
  • Immobile, frail or vulnerable patients who cannot leave the department and would require an uptake room in any case.
  • Patients whose fasting blood sugar at the SOC PET was \>11.0 mmol/l
  • Unable to swallow.
  • Patients with nasogastric tubes, percutaneous gastrostomy or other non-anatomical routes for nutrition.
  • Unable to lie flat for 1h (subset of participants - first 5 participants only).
  • Claustrophobia requiring medication.
  • Undergoing active treatment or assessment of an upper digestive tract tumor (stomach/esophagus)
  • Unable to provide written consent
  • Patients receiving biguanide anti-hyperglycemic agents (e.g. Metformin).
  • Insulin dependent diabetics.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTOral FDG scan

Evaluating the feasibility, scan quality and ease of administration when FDG is consumed orally rather than administered by IV.


Locations(1)

BC Cancer Vancouver

Vancouver, British Columbia, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07295171


Related Trials